HBIO Harvard Bioscience Inc.

Harvard Bioscience to attend Benchmark’s 9th Annual Discovery One-on-One Conference

Harvard Bioscience to attend Benchmark’s 9th Annual Discovery One-on-One Conference

HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference. The virtual event will take place on Wednesday, November 18, 2020 with virtual investor meetings held throughout the day. 

To schedule a meeting with management, please contact your Benchmark Company representative or Vince Curatola at or .

A copy of the materials to be presented at the conference will be available on the investor relations page of the Harvard Bioscience website on November 18, 2020 at 8:00 AM ET.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and clinical research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at .

For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999.



EN
16/11/2020

Underlying

HBIOHarvard Bioscience Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Preliminary Fourth Quarter Financial Resu...

Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single-digit EBITDA growth in 2026Outlines strategy focused on positioning the company as a leader in the growing translational science tools market while expanding consumables revenue and improving operational performance HOLLISTON, Mass.,...

February 10, 2026 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Strategic Consolidation of Manufacturing ...

Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028 while improving throughput and execution HOLLISTON, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced a strategic conso...

January 29, 2026 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces the Successful Completion of Debt Refinan...

Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities  HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced it entered into an agreement with BroadOak Capital Partners (collectively, “BroadOak”), a...

December 17, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Third Quarter 2025 Financial Results

Harvard Bioscience Announces Third Quarter 2025 Financial Results Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by OperationsCompany Expects to Refinance or Repay the Debt in the Fourth QuarterFourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline HOLLISTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2025. “Our third-quarter performance hig...

November 6, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Ca...

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch